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Conclusions: According to ICRU 83 report, to correctly evaluate PTV 
volumes extended outside the body surface, several methods have 
been proposed, for example by extending the beam intensity values 
from the breast periphery to the regions outside the body. By 
attributing a density value to PTV-SV2 we were able to achieve this 
same goal even without the use of any inverse IMRT tools. 
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Purpose/Objective: Different techniques of accelerated partial breast 
irradiation have been described in the literature. Using a volumetric 
modulated arctherapy technique (VMAT) allow a better target 
coverage and better protection of critical organs compare to three-
dimensional conformal radiotherapy (RC3D). We present here the 
dosimetric results of the first patients treated with CRLC Val d'Aurelle 
in Montpellier for an accelerated treatment (IPAS). 
Materials and Methods: Between may 2011 and July 2012, ten 
patients were treated by IPAS for breast cancer using a VMAT 
technique. Dose was 40 Gy, 4 Gy per fraction twice fractions per day 
separate from 6 hours, spread over a week. PTV was generated by 
expansion of the lumpectomy cavity of 1.8 cm. Treatment was 
delivered by two arcs of 270 degrees using the technology RapidArc 
(Varian 21 EX) with a collimator rotation of 45 degrees. The 
optimization and dose calculation were performed with version 
10.0.28 of the planning system and Eclipse AAA algorithm with a 2.5 
mm calculation grid. The constraints were for the PTV D99% ≥ 95%, D95% 
≥ 100% of the prescribed dose. For the ipsilateral lung: V20Gy <3% V10Gy 
<10% V5Gy <20% and V20Gy <1% V10Gy <2% V10Gy <3% for the contralateral 
one. Concerning the eart for V20Gy <1% V5Gy <70%. 
Results: The average volume of the PTV was 99.9 cc [39.8 to 219.5] 
(mean and range). An average of 95% of the PTV received 99.7% of the 
prescribed dose [99.4 to 99.9]. Hotspots: V110Gy represented 0.34% [0 
to 1.42] PTV. The homogeneity index defined as: HI = (D2% - D98%) / D median 
was 0.056 [0.040 to 0.085]. The dose to healthy tissues (OAR) was 
optimal. For the ipsilateral lung V20Gy was 0.27% [0 to 2.67], the V10Gy 
1.60% [0 to 10.47], 6.17% V5Gy [0 to 19.94] . Regarding the 
contralateral lung V20Gy and V10Gy are equal to 0% and V5Gy to 0.28% [0 
to 2.78]. For the heart V5Gy was 3.10% [0 to 23.59], all other 
constraints were largely reached. The average number of monitor unit 
was issued 580UM [473-655] and the processing time was 3.2 minutes 
for two arcs. 
Conclusions: IPAS by RapidArc provides excellent coverage of the PTV 
while preserving healthy tissue. Processing speed improves its quality 
because intrafractions movements are reduced. We have not observed 
severe acute toxicities. 
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Purpose/Objective: To evaluate compliance of patients with 
carcinoma breast to cancer directed therapy in multidisciplinary 
cancer care setting. 
Materials and Methods: The study included a total of 117 patients. 
Patients were assessed as per patient, disease & treatment related 
factors. Surgery included modified radical mastectomy or breast 
conservation surgery. Chemotherapy comprised of 6 cycles of FEC 
based or 4 FEC/4Docetaxel in neoadjuvant & adjuvant setting 
respectively. Herceptin therapy was offered to patients with 
HER/neu2 overexpression. Radiation therapy delivered was 50 
Gy/25#/5 wks, a boost of 16Gy/8#/1.5 wks was delivered to the 
lumpectomy cavity for patients undergoing BCS. All patients were 
considered for tamoxifen/aromatase inhibitors depending upon 
receptor & menopausal status. For the purpose of study compliance 
was defined as all patients who were able to complete the stipulated 
treatment (excluding the hormone therapy) as intended at the 
primary multidisciplinary clinic The key factors evaluated for 
compliance and overall treatment time were date of initiation of 
cancer directed therapy, surgery date, chemotherapy initiation & 
completion dates, radiation start & completion date. Overall 
treatment time was calculated from the day of initiation of cancer 
directed therapy to completion of therapy (before the initiation of 
hormone therapy). 
Results: Seventy percent of the patients presented in loco-regionally 
advanced disease. Most of the patients (66%) were between 40-69 
years of age group. Receptor status positivity for Estrogen and 
progesterone receptor were 43% & 36 % respectively whereas Her-
2/neu was over-expressed in 36% of the patients. Eighty nine percent 
of the patients were subjected to curative therapy whereas 11% of the 
patients were subjected to palliative treatment. Modified radical 
mastectomy was performed in 72% of the patients whereas only 14% of 
the patients underwent breast conservation therapy. Neoadjuvant 
chemotherapy was administered in 51%of the patients while 34% of 
the patients received adjuvant chemotherapy. Sixty eight per cent of 
the patients received 50Gy/25#/5 wks whereas 14% received further 
lumpectomy boost. Eighty six per cent of the patients were compliant 
to cancer directed therapy. The overall median treatment time was 
262 (92-335) days.  
Conclusions: Eight six per cent of the patients were compliant to 
cancer directed therapy whereas fourteen per cent of the patients 
failed to comply to the stipulated treatment before the initiation of 
hormonal therapy. For compliant patients the median overall 
treatment time was 262 days. 
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Purpose/Objective: Although electronic health records are currently 
more common place, not all the information can be used in automatic 
processes, mainly due to the use of free text structured to abstract 
certain values in a table related to the health records. The objective 
of this study is to test a simple natural language processor (NLP) for 
automatic identification of tumor size from the pathology report (PR) 
before adjuvant radiotherapy for breast cancer (BC). 
Materials and Methods: Consecutive PRs were identified by searching 
a database of BC patients treated with surgery and adjuvant radiation 
therapy between January - April 2012. The inclusion criteria included: 
(1) patients having an unstructured free-text PR; (2) non-metastatic 
BC; (3) non simultaneous contralateral BC. Our approach starts with 
the detection and extraction of the tumor's size characteristics in 
unstructured free text from an electronic health record source (PR) 
using a simple NLP. Secondly, based on the data extracted, we 
applied different classification trees from the java data-mining open 
source software: weka. Three data mining algorithms were used: J48 
based on C4.5 algorithm, LADtree, and NaiveBayes. A classification 
algorithm not based on data-mining was also applied. The PRs were 
reviewed and annotated by a 3rd year radiation oncology resident 
according to the 7th edition TNM staging system. Finally, an expert 
senior radiation oncologist revised the divergent classification results 
found between the resident and the different algorithms. 
Results: A total of 68 PRs (test set) met the inclusion criteria. The 
pathological tumor size classification is shown (Table). The median PR 
length was 88 words (range, 69–244). Compared to human 
classification (resident), the coincidence rates with the non-data 
mining based algorithm and the J48, LADtree, and NaiveBayes 
algorithms were 86%, 83%, 82%, and 77%, respectively. After the 
expert revision, the coincidence rates between algorithms and human 
classification were: 96%, 93%, 87%, and 82%, respectively. There were 
only 3 errors when using the non-based on data mining algorithm, 
being 5, 9 and 12 when using J48, LADtree, and NaiveBayes 
algorithms, respectively. The errors in the classification by the 
algorithms were mainly due to lack of recognition of multifocal status 
and inflammatory disease. The resident´s classification errors mostly 
resulted from use of the clinical T stage when the PR revealed a 
complete response after neoadyuvant chemotherapy. 
 
 
 
 
 
 
 
 
 
 
